A phase I/II clinical trial of Ad-SGE-REIC for malignant pleural mesothelioma

Trial Profile

A phase I/II clinical trial of Ad-SGE-REIC for malignant pleural mesothelioma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Ad SGE DKK3 gene therapy-Kyorin (Primary)
  • Indications Mesothelioma; Pleural disorders
  • Focus Adverse reactions
  • Sponsors Kyorin Pharmaceutical
  • Most Recent Events

    • 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Jun 2016 New trial record
    • 05 Nov 2015 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top